Clinical trials
Newly Diagnosed Glioblastoma clinical trials
Below are recruiting newly diagnosed glioblastoma clinical trials, each written for real people, not researchers. We’re tracking 53 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07326566RecruitingPhase 2
Silevertinib and chemo for a type of glioblastoma
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
Birmingham, AlabamaAges 18 years+ - NCT04903795RecruitingPhase 1
Testing a targeted immune therapy for EGFR-mutant glioblastoma
This Phase 1 trial tests BRiTE, a custom immune “match” therapy designed to attack glioblastoma cells that have a specific EGFRvIII change. It’s for adults with newly diagnosed or recurring grade 4 glioblastoma, aiming to see safety and whether the treatment can shrink or control tumors.
Durham, North CarolinaAges 18 years+ - NCT07021339RecruitingPhase 3
Temporal lobectomy for glioblastoma trial
This trial tests if removing part of the temporal lobe (anterior temporal lobectomy) improves outcomes for people with newly diagnosed glioblastoma that is only in the temporal lobe. It aims to see if this surgery can safely remove the entire tumor.
Bonn, North Rhine-WestphaliaAges 18–74 - NCT05380349RecruitingEarly Phase 1
Personalized testing of drugs for glioblastoma stem cells
This early trial tries to find which medicines might work best for your specific glioblastoma, by testing drugs on cancer “stem cell” samples. If the test finds promising drug options, it may guide a more personalized treatment approach.
Seattle, WashingtonAges 18 years+ - NCT06991101RecruitingPhase 2
Ruxolitinib with radiation and chemo for new glioblastoma
This trial tests adding ruxolitinib, a targeted drug, to the standard radiation and chemotherapy for newly diagnosed glioblastoma. It aims to see if this combination helps people live longer without their cancer growing.
Miami, FloridaAges 18 years+ - NCT06556563RecruitingPhase 3
Optune with chemo and immunotherapy for new glioblastoma
This trial tests whether adding the Optune device (a wearable electric field therapy) to standard chemotherapy (temozolomide) and the immunotherapy drug pembrolizumab can help people with newly diagnosed glioblastoma live longer. You may be able to join if you've completed initial radiation and chemo, and have not received certain immunotherapies before.
Phoenix, ArizonaAges 18 years+ - NCT07225621RecruitingPhase 2
Light and sound therapy for newly diagnosed glioblastoma
This trial tests a new approach that uses a light-sensitive drug and low-intensity ultrasound to make standard chemotherapy more effective for glioblastoma. If you have completed initial treatment with radiation and temozolomide without the tumor growing, you may be eligible.
Boston, MassachusettsAges 18–80 - NCT03213002RecruitingPhase 1/Phase 2
CAPTEM pills after brain radiation for newly diagnosed glioblastoma
This trial studies whether taking two chemotherapy pills (capecitabine and temozolomide) after the initial 6-week radiation-and-chemo phase can help people with newly diagnosed glioblastoma. It aims to test safety and early effectiveness right before the usual maintenance temozolomide phase.
New York, New YorkAges 18–74 - NCT04443010RecruitingPhase 1/Phase 2
Testing a new protein drug with standard treatment for new glioblastoma
This Phase 1/2 study tests whether adding a drug called L19TNF to standard chemoradiotherapy is safe and may work better than standard treatment alone for newly diagnosed glioblastoma. If you qualify, you would be closely monitored for side effects and treatment response.
ZurichAges 18 years+ - NCT05271240RecruitingPhase 3
Targeted brain-artery drug added to standard treatment for new GBM
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
New York, New YorkAges 18 years+ - NCT05734560RecruitingPhase 1/Phase 2
Study drug via brain catheter for newly diagnosed GBM
This Phase 1/2 trial tests two experimental treatments delivered through a thin catheter placed in the brain for people with newly diagnosed glioblastoma (GBM). The goal is to see whether the treatment can be given safely and whether it may shrink or control the tumor after standard chemotherapy and radiation.
Durham, North CarolinaAges 18 years+ - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Chicago, IllinoisAges 18 years+ - NCT05864534RecruitingPhase 2
Ultrasound plus immune treatment after new glioblastoma diagnosis
This trial tests whether using focused ultrasound to help adjust the immune system can improve outcomes for people with newly diagnosed glioblastoma. You’d already complete standard brain radiation (with or without temozolomide), then undergo an ultrasound-based immune modulation approach.
Chicago, IllinoisAges 18 years+ - NCT05879250RecruitingPhase 2
WP1066 plus radiation for newly diagnosed glioblastoma
This trial tests whether the study drug WP1066 combined with radiation can better control newly diagnosed glioblastoma, a fast-growing brain tumor. It also aims to check safety and how well tumors respond by using brain scans.
Chicago, IllinoisAges 18 years+ - NCT05879367RecruitingPhase 1
Eflornithine plus temozolomide for newly diagnosed brain cancer
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
Birmingham, AlabamaAges 18 years+ - NCT06222138Recruiting
Biomarker study of TTFields in newly diagnosed glioblastoma
This trial looks at how well Tumor Treating Fields (TTFields) therapy works for people with newly diagnosed glioblastoma. Researchers will study blood and tumor samples to find markers that might predict how well the treatment works.
ToulouseAges 18 years+ - NCT06595186RecruitingPhase 2
JK-1201I plus temozolomide for newly diagnosed glioblastoma
This trial tests a new drug called JK-1201I combined with the standard chemotherapy temozolomide after you finish your initial radiation and chemo. It is for people with newly diagnosed glioblastoma who have had most of their tumor removed and are now ready for the next phase of treatment.
BeijingAges 18–75 - NCT06622434RecruitingPhase 1/Phase 2
Vaccine for glioblastoma after standard treatment
This trial tests an experimental vaccine for glioblastoma, given after the usual radiation and chemotherapy (temozolomide). The goal is to see if the vaccine helps the immune system fight remaining cancer cells.
Paris, IdfAges 18–75 - NCT06649851RecruitingPhase 2
G-CSF to reduce side effects during glioblastoma treatment
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
Boston, MassachusettsAges 18 years+ - NCT06831526RecruitingEarly Phase 1
Chemoradiation with or without azeliragon for new glioblastoma
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
St Louis, MissouriAges 18 years+ - NCT06964815Recruiting
Silibinin plus standard treatment for newly diagnosed glioblastoma
This trial tests whether adding the supplement silibinin (milk thistle extract) to the usual radiation and chemotherapy can help people with a certain type of aggressive brain cancer live longer. The study is for patients whose tumor tests positive for a protein called STAT3 and whose cancer has not spread.
Bologna, BOAges 18–99 - NCT07141732RecruitingPhase 1
Brain radiation therapy during surgery for new glioblastoma
This trial tests giving a precise dose of radiation directly to the tumor area during surgery for newly diagnosed glioblastoma. The goal is to destroy remaining tumor cells immediately after removal, which may improve outcomes.
Moscow, MoscowAges 40–75 - NCT07143812RecruitingPhase 1
Stem cell gene therapy for newly diagnosed glioblastoma
This trial tests a new stem cell-based gene therapy for people with newly diagnosed glioblastoma who have already received standard treatment. The goal is to see if it is safe and potentially effective.
Seongnam, KyunggidoAges 19–70 - NCT07284069RecruitingEarly Phase 1
Senicapoc and perampanel for newly diagnosed glioblastoma
This trial tests two drugs, senicapoc and perampanel, added to standard treatment for people with newly diagnosed glioblastoma. The goal is to see if they can help slow tumor growth or improve outcomes.
Aarhus, DenmarkAges 18 years+
Hear when a new Newly Diagnosed Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for newly diagnosed glioblastoma?
- Yes. Clin2 currently lists 53 recruiting newly diagnosed glioblastoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a newly diagnosed glioblastoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a newly diagnosed glioblastoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.